Tacatuzumab tetraxetan: Difference between revisions
Jump to navigation
Jump to search
m Protected "Tacatuzumab tetraxetan": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 26: | Line 26: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
| Line 32: | Line 32: | ||
{{humanizedmonoclonals}} | {{humanizedmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 16:39, 20 August 2012
Overview
Tacatuzumab tetraxetan is a humanized monoclonal antibody used to treat cancer. Tacatuzumab has a chelator, tetraxetan. It has a radioisotope, yttrium-90Y.
Template:Humanizedmonoclonals Template:WH Template:WikiDoc Sources